Medical Equipment

Projected Growth of the Global Positron Emission Tomography (PET) Radiotracer Market to Reach $3.61 Billion by 2029

December 8, 2025 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the positron emission tomography (pet) radiotracer market from 2025–2034 with trusted insights from The Business Research Company

What CAGR And Valuation Are Anticipated For The Positron Emission Tomography (PET) Radiotracer Market By The End Of 2029?

The positron emission tomography (pet) radiotracer market size has experienced robust growth over recent years. It is anticipated to expand from $2.35 billion in 2024 to $2.54 billion in 2025, achieving a compound annual growth rate (CAGR) of 8.3%. The historical period’s growth can be ascribed to the increasing prevalence of infectious diseases, improved awareness and accessibility, the development of novel radiotracers, the rising prevalence of cancer, and a greater emphasis on preventive medicine.

The positron emission tomography (pet) radiotracer market size is projected to experience robust expansion over the coming years. It is anticipated to reach $3.61 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 9.2%. This growth during the projected timeframe is largely due to factors such as broader application scopes, increased regulatory clearances, development in nascent markets, an expanding elderly demographic, and the rising uptake of PET radio scanners. Key trends anticipated within this forecast period encompass advancements in micro-pet technology, synergy with wearable devices, the broadening field of theranostics, the emergence of nano-radiotracers, and the utilization of blockchain for enhanced data security.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19152&type=smp

Which Business Drivers Are Underpinning The Growth Of The Positron Emission Tomography (PET) Radiotracer Market?

The rising occurrence of infectious diseases is anticipated to drive expansion in the positron emission tomography (PET) radiotracer market moving ahead. These diseases are defined as conditions resulting from pathogenic microorganisms like bacteria, viruses, fungi, or parasites. The growing incidence of infectious diseases stems from factors such as climate change, urbanization, globalization, antibiotic resistance, and shifts in human behavior, all of which aid in pathogen dissemination. Positron emission tomography (PET) radiotracers assist in managing infectious diseases by allowing visualization of metabolic activity and inflammation, thereby facilitating infection detection, evaluating treatment efficacy, and distinguishing between infectious and non-infectious conditions to improve patient outcomes. For example, in February 2024, a report released by the UK Health Security Agency, a government agency based in the UK, indicated that tuberculosis (TB) cases in England rose by 10.7% in 2023, with 4,850 reported cases versus 4,380 in 2022. Consequently, the expanding occurrence of infectious diseases is stimulating the growth of the positron emission tomography (PET) radiotracer market.

What Are The Principal Segment Types In The Positron Emission Tomography (PET) Radiotracer Market?

The positron emission tomography (pet) radiotracermarket covered in this report is segmented –

1) By Radiotracer Type: F-18 (Fluorodeoxyglucose 18), Ga-68 (Fibroblast Activation Protein Inhibitor), Other Radiotracer Types

2) By Application: Cancer, Heart Disease, Gastrointestinal, Endocrine, Neurological Disorders, Other Applications

3) By End-User: Hospitals, Diagnostic Centers, Other End-Users

Subsegments:

1) By F-18 (Fluorodeoxyglucose 18): F-18 FDG (Fluorodeoxyglucose), F-18 Fluoroethyltyrosine (FET), F-18 Florbetapir (Amyloid PET Imaging)

2) By Ga-68 (Fibroblast Activation Protein Inhibitor): Ga-68 Dotatate (Neuroendocrine Tumor Imaging), Ga-68 PSMA (Prostate-Specific Membrane Antigen Imaging), Ga-68 FAPI (Fibroblast Activation Protein Inhibitor Imaging)

3) By Other Radiotracer Types: C-11 (Carbon-11), N-13 (Nitrogen-13), O-15 (Oxygen-15), Rb-82 (Rubidium-82), I-124 (Iodine-124)

Which Long-Term Trends Will Play A Crucial Role In The Positron Emission Tomography (PET) Radiotracer Market?

Major companies within the positron emission tomography (PET) radiotracer market are concentrating on developing advanced diagnostic solutions, such as positron emission tomography imaging agents, to enhance cancer detection and improve patient outcomes. A positron emission tomography (PET) imaging agent is a radioactive substance utilized to visualize and measure biological processes in the body during PET scans. For instance, in March 2023, IsoLogic Innovative Radiopharmaceuticals, a Canada-based radiopharmaceutical company, launched Illuccix, also known as the Ga-68 Gozetotide Preparation Kit (PSMA-11), in Canada as a prostate cancer imaging agent specifically designed to detect metastatic prostate cancer. This tool proves valuable for physicians in identifying metastatic disease and supporting patient management decisions. It is indicated for use in patients suspected of having metastasis who are candidates for initial definitive therapy, as well as in those with suspected recurrence shown by elevated serum prostate-specific antigen (PSA) levels.

Which Companies Are Contributing Significantly To The Positron Emission Tomography (PET) Radiotracer Market Growth?

Major companies operating in the positron emission tomography (PET) radiotracer marker are Cardinal Health Inc., AstraZeneca PLC, Eli Lilly and Company, Siemens Healthineers AG, GE Healthcare Technologies Inc., Philips Healthcare, Bracco Imaging S.p.A., Neusoft Medical Systems Co Ltd., Lantheus Holdings Inc., Jubilant Pharma Limited, SOFIE Biosciences (SOFIE), Yantai Dongcheng Pharmaceutical Group Co. Ltd., Nordion Inc., RefleXion Medical Inc., Isologic Innovative Radiopharmaceuticals, ABX Advanced Biochemical Compounds GmbH, IBA Radiopharma Solutions S.A., IXICO PLC, ImaginAb Inc., Radiomedix Inc.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/positron-emission-tomography-pet-radiotracer-global-market-report

Which Region Offers The Most Opportunity For Positron Emission Tomography (PET) Radiotracer Market Expansion?

North America was the largest region in the positron emission tomography (PET) radiotracer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the positron emission tomography (PET) radiotracer marker report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=19152&type=smp

Browse Through More Reports Similar to the Global Positron Emission Tomography (PET) Radiotracer Market 2025, By The Business Research Company

Positron Emission Tomography Pet Scanners Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/positron-emission-tomography-pet-scanners-global-market-report

Single Photon Emission Computed Tomography Spect Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/single-photon-emission-computed-tomography-spect-global-market-report

Emission Monitoring System Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/emission-monitoring-system-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795